Podcasts about neotract

Jason Elmore is the Sr. Manager of Sales and Training Development at NeoTract. With extensive experience in med device startups as well as with the world’s largest medical device and pharmaceutical companies, he knows a thing or two about the patient journey. In this episode, Jason enlightens us on the increasingly popular concept of shared decision making in medicine — and tells us how becoming a key player in the patient’s clinical pathway is one of the best things a MedTech sales rep can do. In this episode, you’ll learn: Why the patient should have a hand in selecting their treatment pathway How to make your medical professional customers “teachers” so they can better interact with their patients The importance of tracking and celebrating your results Why you’re missing an opportunity if you haven’t rethought and adjusted your value proposition for the COVID environment Plus, we create a diagnostic tool to show MedTech reps what to look for when assessing the clinical pathway. Resources and links from the show: Connect with Jason Elmore on LinkedIn Connect with Clark Wiederhold on LinkedIn Connect with Zed Williamson on LinkedIn The Growth-Driven Practice Series The Behavior Change Blueprint Elite Execution: Disciplines & Insights for Extraordinary Salespeople by Jason Elmore

Josh Makower, General Partner, New Enterprise Associates Josh Makower is a General Partner on NEA's healthcare team leading their medtech/healthtech practice. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 8 companies over the past 20 years. Notable transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex in 2017, Nuelle, acquired by Aytu in 2017, Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997 and TransVascular, acquired by Medtronic in 2003. On-going ExploraMed/NEA ventures include Moximed, Willow and Exploramed V. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford's Biodesign Innovation Program. Josh currently serves on the board of directors for DOTS Devices, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow, SetPoint Medical and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women's health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor's degree in Mechanical Engineering from MIT.

In this Medtech Talk Podcast, CEO John Pedersen explains why he chose to help Augmenix roll out its SPACEOAR implant, a hydrogel that's inserted between a patient's prostate and rectum to save healthy tissue from radiation exposure. In this talk, Pedersen discusses the rise of urology - which includes the recent acquisitions of Neotract and NxThera. He also updates listeners on Augmenix's efforts to secure reimbursement. Finally, the former Boston Scientific exec offers advice to anyone working in a global Medtech company.

Join us on Thursday at the Medtech Conference in Minneapolis to hear from Congressman Erik Paulsen. A longtime proponent of the Medtech industry, Rep. Paulsen most recently co-authored a letter asking the Trump administration to remove medical technology products from a list of Chinese imports subject to protective tariffs. The five-term Congressman also has fought against the Medical Device Tax. The Medtech Conference co-chairs and advisory board also are pleased to honor Dave Amerson, CEO of NeoTract, as the recipient of this year’s Dealmaker of the Year Award. The award recognizes Amerson's leadership of the urology start-up as it established its UroLift System as a critical treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Sales of UroLift were surging when Teleflex agreed to acquire the company, paying $725 million up front with the promise of another $375 million in milestone payments over the next two years. In an interview, Justin Klein, general partner of NEA, and Amerson will discuss: The steps Neotract took to adopt a winning culture? What strategies helped the company secure support from payers, providers? How the deal with Teleflex came to be? What's next for Teleflex in Urology? Join us on May 31st to explore this singular successful story and to better understand our entire Medtech sector.

Exits Johnson & Johnson is celebrating an exit with the acquisition of its portfolio company NeoTract by Teleflex for a total consideration of $1.1bn. Intel Capital also celebrated an exit as its portfolio company StarCash, a digital gift card service, was acquired by fintech company Blackhawk Network for $175m in cash. Madsack hails CleverShuttle Paytm to make … Continue reading "11 September 2017 – Judging Purchase Versus Investment"

Biz Stone, the co-founder of Twitter, has famously stated, “Timing, perseverance, and 10 years of trying will eventually make you look like an overnight success.” In the world of medtech startups, this is almost always the case. And it’s certainly true with UroLift, a device that came to life in the fall of 2004...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?How Will These 2 Major Healthcare Changes Affect Medical Device Companies?